Equities
Health CareMedical Equipment and Services
  • Price (SEK)112.00
  • Today's Change2.70 / 2.47%
  • Shares traded67.36k
  • 1 Year change+25.21%
  • Beta1.3970
Data delayed at least 15 minutes, as of Mar 28 2024 12:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

AddLife AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company markets and sells instruments, equipment, consumables and related services mainly to the healthcare sector. The Company operates through two segments: The LabTech segment is engaged in the sales of laboratory equipment, analytical instruments and reagents, that are used for diagnostics or biomedical research; The MedTech segment offers various medical device equipment, consumables, instruments and devices, primarily to hospitals. The Company operates through number of subsidiaries, such as BergmanLabora AB, BioNordica group, Holm & Halby A/S, Immuno Diagnostic Oy, LabRobot Products AB, Triolab-group, Active Care Sverup AB, Fenno Medical Oy, Mediplast AB, among others.

  • Revenue in SEK (TTM)9.69bn
  • Net income in SEK191.00m
  • Incorporated2014
  • Employees2.31k
  • Location
    AddLife ABBrunkebergstorg 5, Box 3145STOCKHOLM 103 62SwedenSWE
  • Phone+46 842003830
  • Websitehttps://www.add.life/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Nykode Therapeutics ASA136.78m-372.69m4.83bn168.00--2.66--35.30-1.36-1.360.50475.650.0601--10.14---16.365.65-19.006.38-----272.4718.13----0.0324--79.99282.1717.75--187.37--
Calliditas Therapeutics AB1.21bn-466.18m6.84bn181.00--18.40--5.67-8.69-8.6922.496.240.63325.028.776,667,895.00-24.46-26.46-30.27-30.2794.99---38.63-76.593.08-4.440.7427--50.32---13.08------
Gubra A/S315.88m-68.60m7.33bn219.00--9.88--23.21-2.91-2.9113.5129.44------936,095.90--------56.06---21.72------0.1296--2.82---1,133.04------
Surgical Science Sweden AB882.85m233.97m7.78bn260.0033.211.7926.858.814.594.5917.3285.160.18881.876.153,395,589.005.004.495.314.7869.4270.0626.5023.753.56----0.0010.0168.1424.47--38.57--
Swedencare AB (publ)2.34bn58.60m10.32bn560.00176.071.4328.014.410.36920.369214.7345.400.23952.5010.234,175,714.000.60021.380.61951.4355.2055.342.515.101.991.960.187145.3327.4888.16-37.9620.2430.90--
AddLife AB9.69bn191.00m12.88bn2.31k69.732.6911.491.331.571.5779.4840.690.75073.696.19--1.495.312.258.8337.1636.671.985.790.45411.810.51631.736.6231.30-60.428.0042.31-1.89
BioGaia AB1.30bn365.35m13.02bn213.0036.986.6533.3210.043.623.6212.8420.110.5703------16.0715.4717.4516.9373.2973.3028.1827.70------104.4217.4411.81-2.2511.2029.3528.10
Bonesupport Holding AB591.08m245.02m14.70bn110.0060.7327.4458.2424.873.723.729.048.241.110.71866.605,373,428.0046.20-9.0858.31-11.2891.5190.2541.45-11.652.46--0.0311--79.7643.65459.44--18.39--
BioArctic AB615.99m229.25m15.90bn83.0083.7218.2164.1825.812.582.586.9711.850.6026------22.432.2424.802.5691.7386.5237.229.76----0.00470.00169.83-2.912,150.71-9.69----
Bavarian Nordic A/S10.88bn2.27bn18.65bn1.38k7.961.175.971.7119.4619.4692.83132.470.52811.926.105,121,349.0011.031.2113.621.4865.1853.7220.894.061.35--0.01390.00124.1469.78524.66--35.76--
Vitrolife AB3.51bn-3.85bn27.09bn1.11k--2.13--7.72-28.44-28.4425.9393.930.19043.757.34---20.89-4.57-21.60-4.7856.3158.38-109.71-21.892.545.980.141--8.6024.99-1,077.41---8.903.30
Camurus AB1.72bn431.44m30.02bn204.0069.5219.4167.4017.497.497.4930.1126.841.071.177.29--26.85-1.1333.67-1.4192.8790.0525.13-1.634.13--0.0162--79.52103.39676.63--14.06--
ALK-Abello A/S7.43bn748.84m38.73bn2.82k59.316.1732.355.212.092.0920.9020.100.74021.326.111,708,215.007.463.509.424.3762.9160.6610.075.071.1835.050.14680.006.9410.6045.07--16.32--
Data as of Mar 28 2024. Currency figures normalised to AddLife AB's reporting currency: Swedish Krona SEK

Institutional shareholders

48.89%Per cent of shares held by top holders
HolderShares% Held
SEB Investment Management ABas of 21 Nov 202312.25m10.40%
AMF Fonder ABas of 31 Jul 20237.72m6.55%
Fidelity Management & Research Co. LLCas of 31 Jan 20246.70m5.68%
Cliens Kapitalf�rvaltning ABas of 14 Feb 20246.34m5.38%
ODIN Forvaltning ASas of 29 Feb 20244.93m4.18%
F�rsta AP-fondenas of 31 Jul 20234.66m3.96%
Didner & Gerge Fonder ABas of 31 Dec 20224.01m3.41%
ODIN Forvaltning AS (Sweden)as of 29 Feb 20244.00m3.40%
The Vanguard Group, Inc.as of 07 Mar 20243.96m3.36%
Fj�rde AP-fondenas of 30 Jun 20233.04m2.58%
More ▼
Data from 31 Dec 2022 - 29 Feb 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.